Condition:   Prostate Cancer
Intervention:   Other: 11C Acetate Imaging
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified May 2012

Conditions:   Bone Metastases;   Castrate-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: cabozantinib;   Other: laboratory biomarker analysis;   Procedure: magnetic resonance imaging
Sponsors:   University of Chicago;   University of Chicago;   NorthShore University Health System
Recruiting - verified May 2012

Condition:   Metastatic Castration-resistant Prostate Cancer
Interventions:   Drug: Cabazitaxel;   Drug: Mitoxantrone;   Drug: Prednisone;   Drug: Pegfilgrastim
Sponsors:   University of California, San Francisco;   Andrea Harzstark;   Sanofi-Aventis
Not yet recruiting - verified May 2012

Conditions:   Lung Cancer;   Solid Tumor (Not Breast or Prostate Cancers)
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: Saw Palmetto
Sponsors:   Michigan State University;   Michigan State University
Recruiting - verified April 2012

Conditions:   Benign Prostatic Hyperplasia;   Lower Urinary Track Symptoms
Interventions:   Drug: onaBoNT-A + placebo;   Drug: Tamsulosin + placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Not yet recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   U.S. Army Medical Research Acquisition Activity;   Dusten Macdonald, MD;   The Geneva Foundation
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   U.S. Army Medical Research Acquisition Activity;   Dusten Macdonald;   The Geneva Foundation
Recruiting - verified April 2012

Condition:   Early Stage Prostate Cancer
Intervention:   Behavioral: Acceptance and Commitment Therapy
Sponsors:   Veterans Medical Research Foundation;   Veterans Medical Research Foundation;   Alliant International University;   University of California, San Diego
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: abiraterone acetate;   Drug: prednisone;   Drug: veliparib
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Advanced Solid Tumor;   Lymphoma
Intervention:   Drug: DS-3078a
Sponsors:   Daiichi Sankyo Inc.;   Daiichi Sankyo Inc.
Recruiting - verified April 2012

Condition:   Prostate Neoplasms
Intervention:   Radiation: "TrueBeam" stereotactic body radiosurgery
Sponsors:   Main Line Health;   Albert DeNittis
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabozantinib;   Drug: Abiraterone
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Prostate Carcinoma
Interventions:   Drug: Metformin;   Drug: Simvastatin
Sponsors:   Baylor College of Medicine;   Nicholas Mitsiades
Recruiting - verified March 2012

Conditions:   Nocturia;   Benign Prostatic Hyperplasia;   Incontinence
Interventions:   Drug: onaBoNT-A + placebo;   Drug: Tamsulosin + placebo
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Department of Veterans Affairs
Not yet recruiting - verified May 2012

Condition:   Cancer Related Fatigue
Interventions:   Behavioral: Qigong;   Behavioral: Non-aerobic stretching
Sponsors:   University of Utah;   University of Utah
Recruiting - verified March 2012

Conditions:   Prostate Cancer;   Robotic Prostatectomy;   Foley Catheter Discomfort
Interventions:   Drug: Bupivacaine;   Drug: Saline
Sponsors:   Columbia University;   Columbia University
Recruiting - verified March 2012

Condition:   Bladder Cancer
Interventions:   Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors;   Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors
Sponsors:   Emory University;   Emory University;   Olympus
Not yet recruiting - verified March 2012

Conditions:   Prostatic Neoplams;   Prostate Cancer;   Neoplasm, Prostate;   Neoplasm,Prostatic
Interventions:   Drug: AMG 386;   Drug: Abiraterone;   Drug: Prednisone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Stanford University;   Stanford University
Not yet recruiting - verified March 2012

Condition:   Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Intervention:   Drug: Everolimus (RAD001)
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Device: Transperineal Ultrasound
Sponsors:   Fletcher Allen Health Care;   H. James Wallace, MD;   Internal Funding, Elekta Ltd.
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Prostatic Adenocarcinoma
Interventions:   Drug: degarelix injection;   Drug: degarelix injection
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Ferring Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostatic Neoplasm
Intervention:   Radiation: radiation therapy
Sponsors:   Sharp Memorial Hospital;   Sharp Memorial Hospital
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Procedure: Core Needle TRUS Needle biopsy (Transrectal ultrasound);   Procedure: Core Needle MRI/US image fusion guided needle biopsy
Sponsors:   Philips Healthcare;   Philips Healthcare
Not yet recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: 89Zr-DFO-huJ591
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Weill Medical College of Cornell University;   Broad Institute of MIT and Dana-Farber Cancer Institute of Harvard
Recruiting - verified February 2012

Conditions:   Solid Malignancies;   Metastatic Castrate-resistant Prostate Cancer
Intervention:   Drug: axitinib
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   Pfizer
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Device: SpaceOAR System
Sponsors:   Augmenix, Inc.;   Augmenix, Inc.
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified March 2012

Conditions:   Castration-resistant Prostate Cancer;   Stage IV Prostate Cancer
Intervention:   Drug: abiraterone acetate
Sponsors:   University of Chicago;   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Drug: MDV3100
Sponsors:   Medivation, Inc.;   Medivation, Inc.;   Astellas Pharma Inc
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: linsitinib;   Genetic: RNA analysis;   Other: circulating tumor cell analysis;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: liquid chromatography;   Other: mass spectrometry
Sponsors:   National Cancer Institute (NCI);   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Hot Flashes in Men With Prostate Cancer Receiving Androgen Ablation Therapy
Interventions:   Drug: Gabapentin;   Drug: Venlafaxine
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified February 2012

Conditions:   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: atorvastatin calcium;   Drug: placebo
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Androgen Ablation;   Drug: Cabazitaxel;   Drug: Salvage Therapy;   Drug: Neoadjuvant Treatment - Hormonal Therapy;   Drug: Neoadjuvant Treatment - Cabazitaxel
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Ipilimumab and GM-CSF
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   Bristol-Myers Squibb;   Genzyme
Not yet recruiting - verified February 2012

Condition:   Melanoma
Intervention:   Other: Blood Draw
Sponsors:   Comprehensive Cancer Centers of Nevada;   Wolfram Samlowski;   TrueCells, LLC;   Comprehensive Cancer Centers of Nevada;   The Scripps Research Institute;   University of Pittsburgh
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Prostate Adenocarcinoma
Intervention:   Drug: C11-Sodium Acetate
Sponsors:   Arizona Molecular Imaging Center;   Arizona Molecular Imaging Center
Recruiting - verified April 2012

Condition:   Prostatic Neoplasms
Intervention:   Drug: Radium-223 chloride (BAY88-8223)
Sponsors:   Bayer;   Bayer
Available - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: tivantinib;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Prostate Cancer;   Benign Prostatic Hyperplasia;   Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Intervention:   Drug: BOTOX
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
Recruiting - verified January 2012

Conditions:   Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: sirolimus;   Other: laboratory biomarker analysis;   Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified March 2012

Conditions:   Prostate Cancer;   Castration Resistant Prostate Cancer;   Pain;   Prostatic Neoplasms
Interventions:   Drug: cabozantinib;   Drug: mitoxantrone;   Drug: prednisone
Sponsors:   Exelixis;   Exelixis
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Acai Juice Product
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver
Recruiting - verified January 2012

Condition:   Adenocarcinoma of the Prostate
Interventions:   Radiation: Radiation Therapy;   Drug: Androgen Suppression Therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: tasquinimod;   Drug: tasquinimod 0.25 mg; 0.5 mg;   Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
Sponsors:   Duke University;   Duke University
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   University of Arkansas;   University of Arkansas
Recruiting - verified January 2012

Conditions:   Prostatic Neoplasm;   Prostate Cancer;   Prostatic Adenocarcinoma;   Hormone Refractory Prostate Cancer;   Stage IV Prostate Carcinoma
Interventions:   Drug: Abiraterone acetate plus prednisone;   Drug: Abiraterone acetate plus prednisone;   Drug: Abiraterone acetate plus prednisone
Sponsors:   University of Washington;   University of Washington;   Janssen, LP
Not yet recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel;   Drug: Prednisone;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Sanofi-Aventis
Not yet recruiting - verified January 2012

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: abiraterone acetate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Not yet recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Drug: PLX3397
Sponsors:   Plexxikon;   Plexxikon
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: Se-methyl-seleno-L-cysteine;   Dietary Supplement: selenomethionine;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Robert H. Lurie Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Intervention:   Biological: Ipilimumab
Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Prostate Cancer Metastatic;   Hormone Refractory Prostate Cancer
Interventions:   Biological: sipuleucel-T;   Drug: abiraterone acetate
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Condition:   Benign Prostatic Hyperplasia (BPH)
Interventions:   Device: Greenlight XPS Laser;   Device: BiVAP Saline Vaporization of the prostate
Sponsors:   Brooklyn Urology Research Group;   Brooklyn Urology Research Group;   American Medical Systems;   Richard Wolf Medical Instruments Corporation (RWMIC)
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Caris Science, Inc.;   Caris Science, Inc.
Recruiting - verified January 2012

Conditions:   Solid Tumors;   Prostate Cancer
Intervention:   Drug: ADI-PEG 20
Sponsors:   Polaris Group;   Polaris Group
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Drug: 18F-DCFBC
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Drug: GDC-0068;   Drug: GDC-0980;   Drug: placebo;   Drug: abiraterone;   Drug: prednisone
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Cancer
Intervention:   Drug: I-131-CLR1404
Sponsors:   Novelos Therapeutics;   Novelos Therapeutics
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Radiation: CyberKnife Boost
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Radiation: Proton Radiation;   Drug: Androgen Suppression Therapy
Sponsors:   Proton Collaborative Group;   Proton Collaborative Group
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: kanglaite gelcap;   Drug: Kanglaite gelcap
Sponsors:   KangLaiTe USA;   KangLaiTe USA
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Drug: 99mTc-MIP-1404
Sponsors:   Molecular Insight Pharmaceuticals, Inc.;   Molecular Insight Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Degarelix
Sponsors:   Ferring Pharmaceuticals;   Ferring Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   University Urological Associates Inc.;   University Urological Associates Inc.
Not yet recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Other: PROCASE Decision-Aid
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Procedure: ultrasound imaging;   Procedure: robot-assisted laparoscopic surgery
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Procedure: Sodium Flouride (NaF) Positron Emission Tomograpy/Computed Tomography (PET/CT) imaging
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified January 2012

Conditions:   Kidney Cancer;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Prostate Adenocarcinoma
Intervention:   Other: Polymer based fiducial placement
Sponsors:   ProCure Proton Therapy Center;   John Chang, MD
Recruiting - verified December 2011

Condition:   Castration Resistant Prostate Cancer
Intervention:   Drug: NRX 194204
Sponsors:   Io Therapeutics;   Io Therapeutics
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Drug: Colchicine
Sponsors:   Penn State University;   Penn State University
Not yet recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: Lovastatin
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Radiation;   Drug: Androgen Deprivation Therapy (ADT);   Other: Standard of care;   Drug: L-BLP25
Sponsors:   EMD Serono;   EMD Serono
Recruiting - verified December 2011

Conditions:   Diarrhea;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: cabazitaxel;   Drug: prednisone;   Drug: octreotide pamoate;   Other: questionnaire administration;   Drug: octreotide acetate
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   National Cancer Institute (NCI);   Sanofi-Aventis
Not yet recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: docetaxel;   Drug: pasireotide;   Drug: prednisone
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Carcinoid Tumor;   Pancreatic Neuroendocrine Tumor
Intervention:   Drug: Cabozantinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Not yet recruiting - verified November 2011

Conditions:   CD27 Expressing B-cell Malignancies;   CD27 Expressing Solid Tumors;   Chronic Lymphocytic Leukemia;   Burkett's Lymphoma;   Mantle Cell Lymphoma;   Primary Lymphoma of the Central Nervous System;   Marginal Zone B Cell Lymphoma;   Solid Tumor;   Metastatic Melanoma;   Renal (Clear) Cell Carcinoma;   Hormone-refractory Prostate Adenocarcinoma;   Ovarian Cancer;   Colorectal Adenocarcinoma;   Non-small Cell Lung Cancer
Intervention:   Drug: CDX-1127
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Cancer
Intervention:   Drug: GSK2636771
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Cancer
Interventions:   Behavioral: Post-Test Questionnaire;   Behavioral: Interviews;   Behavioral: Focus Groups
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Department of Defense
Not yet recruiting - verified April 2012

Conditions:   Conditions Influencing Health Status;   Healthy;   Prostate Cancer
Interventions:   Other: laboratory biomarker analysis;   Procedure: transrectal prostate biopsy
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Benign Prostatic Hyperplasia
Intervention:   Drug: NX-1207
Sponsors:   Nymox Corporation;   Nymox Corporation
Recruiting - verified November 2011

Conditions:   Prostate Cancer;   Metastatic Disease
Intervention:   Drug: Itraconazole
Sponsors:   Stanford University;   Stanford University
Recruiting - verified October 2011

Condition:   Prostate Cancer
Interventions:   Biological: AdV-tk + valacyclovir;   Biological: Placebo + valacyclovir
Sponsors:   Advantagene, Inc.;   Advantagene, Inc.
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Breast Cancer;   Lung Cancer;   Ovarian Cancer;   Lymphoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Not yet recruiting - verified March 2012

Conditions:   Prostate Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexual Dysfunction
Intervention:   Radiation: hypofractionated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Non-small Cell Lung Cancer (NSCLC);   Stage IV NSCLC;   Metastatic NSCLC
Interventions:   Drug: Cabazitaxel-XRP6258;   Drug: Cabazitaxel-XRP6258
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: metformin;   Drug: Placebo
Sponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI);   University of Arizona
Not yet recruiting - verified October 2011

Conditions:   Alcohol Dependence;   Anxiety
Interventions:   Drug: Doxazosin;   Drug: Placebo
Sponsors:   Brown University;   Brown University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Drug: APC-100
Sponsors:   Adamis Pharmaceuticals Corporation;   Adamis Pharmaceuticals Corporation
Recruiting - verified September 2011

Condition:   Prostate Cancer Metastatic
Intervention:   Drug: Cabozantinib
Sponsors:   University of Michigan Cancer Center;   David C Smith;   Exelixis
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Lapatinib;   Radiation: Radiation therapy
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:   Device: Radio-Frequency Ablation (RFA) ENCAGE™
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Trod Medical, US,LLC
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors:   GP-Pharm;   GP-Pharm
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel;   Radiation: Intensity Modulated Radiation Therapy (IMRT);   Drug: Anti-Androgen Therapy: Bicalutamide;   Genetic: Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Sanofi-Aventis
Recruiting - verified January 2012

Conditions:   Prostatic Neoplasm;   Prostate Cancer;   Prostatic Adenocarcinoma
Interventions:   Biological: sipuleucel-T;   Drug: leuprolide acetate
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: PSMA ADC
Sponsors:   Progenics Pharmaceuticals, Inc.;   Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011

Condition:   Prostate Cancer
Intervention:   Drug: PSMA ADC
Sponsors:   Progenics Pharmaceuticals, Inc.;   Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011

Condition:   Prostate Cancer
Intervention:   Radiation: Prostate SBRT with concurrent boost to intraprostatic lesion(s)
Sponsors:   Rocky Mountain Cancer Centers;   Rocky Mountain Cancer Centers;   Dr. Dennis Carter
Recruiting - verified August 2011

Conditions:   Prostate Cancer;   Prostate Adenocarcinoma
Interventions:   Radiation: Standard Salvage Radiation Treatment (SSRT);   Radiation: Mapped Tumor Salvage RT (MTSRT);   Procedure: DCE-MRI of Pelvis/Prostate;   Procedure: Bone Scan;   Procedure: Ultrasound Prostate Bed Biopsy;   Procedure: Urine Sample Collection;   Procedure: Blood Sample Collection;   Behavioral: EPIC SF-12 Questionnaire;   Behavioral: MAC-PC Questionnaire
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Other: Placebo;   Drug: Methylphenidate;   Behavioral: Counseling Sessions;   Other: Sham Exercise;   Other: Standardized Exercise Intervention Program;   Other: Cognitive Behavioral Therapy (CBT)
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   American Cancer Society
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Prostate Adenocarcinoma
Interventions:   Radiation: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy;   Radiation: Standard IMRT;   Behavioral: EPIC SF-12 Questionnaire;   Behavioral: MAX-PC Questionnaire;   Behavioral: IPSS Questionnaire;   Procedure: Blood Sample Collection;   Procedure: Urine Sample Collection;   Procedure: Prostate Biopsy;   Procedure: CT Simulation;   Procedure: MRI Simulation;   Procedure: Fiducial Gold Marker Placement
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012

Conditions:   Prostate Cancer;   Prostate Adenocarcinoma
Interventions:   Radiation: Standard Fractionated Intensity Modulated Radiotherapy (SIMRT);   Radiation: Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT);   Behavioral: EPIC SF-12 Questionnaire;   Behavioral: MAX-PC Questionnaire;   Behavioral: IPSS Questionnaire;   Procedure: Ultra-Sound Guided Biopsy;   Procedure: Prostate Fiducial Marker Placement;   Procedure: Blood Sample Collection;   Procedure: DCE-MRI;   Procedure: CT Simulation;   Procedure: MRI Simulation;   Procedure: Bone Scan
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Procedure: Fascial suturing;   Procedure: Lymph node template
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Other: ADT Therapy;   Drug: Axitinib;   Procedure: Prostatectomy
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified April 2012

Conditions:   Prostate Neoplasms;   Prostate Cancer
Interventions:   Drug: Cohort 4;   Drug: Cohort 3;   Drug: Cohort 2;   Drug: Cohort 1
Sponsors:   Cougar Biotechnology, Inc.;   Cougar Biotechnology, Inc.
Recruiting - verified May 2012

Condition:   Adenocarcinoma of the Prostate
Intervention:   Device: Prostate gland immobilization with rectal balloon
Sponsors:   Wheaton Franciscan Healthcare;   James Taylor
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Pancreatic Cancer;   Melanoma;   Renal Cell Carcinoma;   Ovarian Cancer;   Colorectal Cancer;   Gastric Cancer;   Bladder Cancer;   Non-small Cell Lung Cancer;   Glioblastoma
Intervention:   Biological: MGA271
Sponsors:   MacroGenics;   MacroGenics
Recruiting - verified December 2011

Condition:   Advanced Cancers
Intervention:   Behavioral: Telephone Survey
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone acetate;   Drug: Dutasteride;   Drug: Prednisone
Sponsors:   Dana-Farber Cancer Institute;   Mary-Ellen Taplin, MD
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Metastatic
Intervention:   Drug: BKM120
Sponsors:   Duke University;   Duke University;   Novartis Pharmaceuticals
Recruiting - verified October 2011

Conditions:   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: axitinib;   Procedure: therapeutic conventional surgery;   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Device: RapidStrand seeds for use with 18g needle;   Device: ThinStrand
Sponsors:   Prostate Cancer Foundation of Chicago;   Prostate Cancer Foundation of Chicago
Recruiting - verified June 2011

Condition:   Prostate Cancer
Interventions:   Device: Artificial urinary sphincter;   Device: InVance Sling;   Device: AdVance Sling;   Device: Virtue Sling;   Drug: Contigen
Sponsors:   Stanford University;   Stanford University
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasms
Intervention:   Device: Visualase Thermal Therapy System
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Pazopanib;   Drug: Docetaxel;   Drug: Pazopanib;   Drug: Prednisone
Sponsors:   Duke University;   Duke University;   GlaxoSmithKline
Recruiting - verified July 2011

Condition:   Urinary Incontinence
Interventions:   Drug: solifenacin succinate;   Drug: Placebo
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified March 2012

Condition:   Hypogonadism
Interventions:   Drug: Testosterone Cypionate;   Drug: Placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   St. Joseph Hospital of Orange;   St. Joseph Hospital of Orange
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Radiation: Proton Radiation Therapy
Sponsors:   University of Florida;   University of Florida
Recruiting - verified March 2012

Conditions:   Prostatic Neoplasms;   Adenocarcinoma
Interventions:   Procedure: Robotic Radical Prostatectomy;   Procedure: Open Radical Prostatectomy
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified September 2011

Conditions:   Urinary Incontinence;   Mood
Intervention:   Behavioral: BF+GROUP; BF+PHONE
Sponsors:   Case Western Reserve University;   Case Western Reserve University;   National Institutes of Health (NIH)
Recruiting - verified May 2011

Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Glioblastoma Multiforme;   Head and Neck Squamous Cell Cancer;   Triple Negative Breast Cancer;   Hormone Receptor-Positive Breast Cancer;   Castration-Resistant Prostate Cancer;   Ewing's Family of Sarcomas
Intervention:   Drug: CC-115
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Other: Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of Colorado, Denver;   M.D. Anderson Cancer Center;   North Shore Long Island Jewish Health System
Recruiting - verified April 2012

Condition:   Prostate Cancer Metastatic
Interventions:   Drug: EMD 525797;   Drug: EMD 525797;   Other: Placebo
Sponsors:   EMD Serono;   EMD Serono
Recruiting - verified May 2012

Conditions:   Castration-resistant Prostate Cancer,;   Metastatic Breast Cancer
Intervention:   Drug: LFA102
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified May 2012

Condition:   Prostatic Neoplasm
Intervention:   Drug: EZN-4176
Sponsors:   Enzon Pharmaceuticals, Inc.;   Enzon Pharmaceuticals, Inc.
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasms
Intervention:   Drug: Cabazitaxel plus bavituximab
Sponsors:   University of California, Irvine;   University of California, Irvine;   Peregrine Pharmaceuticals
Recruiting - verified August 2011

Condition:   Prostate Cancer Metastatic
Interventions:   Biological: PROSTVAC-V/F-TRICOM + GM-CSF;   Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo;   Biological: Placebo
Sponsors:   BN ImmunoTherapeutics;   BN ImmunoTherapeutics
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: Vitamin D and Genistein;   Other: Placebo
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   University of Alabama at Birmingham;   University of Rochester;   University of Minnesota - Clinical and Translational Science Institute;   Lahey Clinic;   Urology San Antonio
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Biological: pTVG-HP;   Biological: rhGM-CSF
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified February 2012

Condition:   Healthy
Intervention:   Drug: Testosterone 1% gel (or placebo) + acyline (or placebo)
Sponsors:   University of Washington;   University of Washington;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
Not yet recruiting - verified June 2011

Conditions:   Brain Cancer;   Breast Cancer;   Prostate Cancer
Intervention:   Drug: 18F-fluoroacetate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Other: Questionnaire
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   The Cleveland Clinic;   Johns Hopkins University;   University of California, San Francisco;   University of Michigan;   Vanderbilt University;   Washington University School of Medicine
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: Muscadine Plus Grape Skin Extract
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   Howard University;   Department of Defense: Prostate Cancer Clinical Trial Consortium
Recruiting - verified March 2011

Conditions:   Castrate Resistant Prostate Cancer;   Chemotherapy Naive Prostate Cancer;   Prostate Cancer
Interventions:   Drug: Pasireotide;   Drug: Combination treatment with SOM230 and Everolimus
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University;   Novartis Pharmaceuticals
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: abiraterone acetate;   Drug: degarelix;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Procedure: orchiectomy
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasm
Intervention:   Drug: abiraterone acetate in combination with prednisone
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Docetaxel (XRP6976);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Conditions:   Locally Advanced Malignant Neoplasm;   Malignant Solid Tumour
Intervention:   Biological: ALT-836 in combination with gemcitabine
Sponsors:   Altor Bioscience Corporation;   Altor Bioscience Corporation
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Drug: sipuleucel-T
Sponsors:   Dendreon;   Dendreon
Recruiting - verified April 2012

Conditions:   Advanced Prostate Cancer;   Prostatic Neoplasms
Intervention:   Biological: sipuleucel-T
Sponsors:   Dendreon;   Dendreon
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Colorectal Cancer;   Prostate Cancer
Interventions:   Behavioral: Standard Arm (mail/telephone);   Behavioral: Internet Arm;   Behavioral: Surveys and Questionnaires;   Behavioral: Exercise and Diet
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Prostate Disease
Intervention:   Device: Plastic Scintillation Detectors
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Drug: Sodium Acetate C11
Sponsors:   Arizona Molecular Imaging Center;   Arizona Molecular Imaging Center
Recruiting - verified April 2012

Condition:   Prostate CA
Interventions:   Drug: Dexamethasone;   Procedure: TAP block
Sponsors:   Steward St. Elizabeth's Medical Center of Boston, Inc.;   Steward St. Elizabeth's Medical Center of Boston, Inc.
Recruiting - verified February 2011

Conditions:   Metastatic Cancer;   Cancer;   Solid Tumors
Intervention:   Drug: BIND-014
Sponsors:   BIND Biosciences;   BIND Biosciences
Recruiting - verified June 2011

Condition:   Prostate Cancer
Intervention:   Drug: Tesetaxel
Sponsors:   Genta Incorporated;   Genta Incorporated
Recruiting - verified March 2012

Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine 8mg;   Drug: Fesoterodine 4mg;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Conditions:   Overactive Bladder;   Bladder, Overactive;   Overactive Urinary Bladder
Interventions:   Drug: Fesoterodine 8 mg;   Drug: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Ferumoxytol
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Prostatic Neoplasms
Interventions:   Drug: MDV3100;   Drug: Bicalutamide
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Medivation, Inc.
Recruiting - verified March 2012

Condition:   Advanced Cancer
Interventions:   Drug: ridaforolimus;   Drug: MK-0752;   Drug: MK-2206
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: Finasteride
Sponsors:   The University of Texas Health Science Center at San Antonio;   The University of Texas Health Science Center at San Antonio;   National Institutes of Health (NIH)
Recruiting - verified August 2011

Condition:   Prostate Cancer
Intervention:   Drug: DSTP3086S
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: Hsp90 inhibitor STA-9090;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Genetic: RNA analysis;   Other: spectrophotometry;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: gene expression analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Prostate Cancer;   Osteopenia;   Osteoporosis
Intervention:  
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls;   Behavioral: Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   National Institutes of Health (NIH);   Center for Marital and Sexual Health of South Florida
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: cediranib maleate;   Drug: dasatinib
Sponsors:   National Cancer Institute (NCI);   Princess Margaret Hospital, Canada;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Prostate Cancer Prevention
Interventions:   Dietary Supplement: sulforaphane glucosinolate capsules;   Dietary Supplement: Gelatin capsule containing cellulose and magnesium stearate
Sponsors:   Portland VA Medical Center;   National Cancer Institute (NCI);   Oregon State University;   Portland VA Medical Center;   OHSU Knight Cancer Institute
Recruiting - verified February 2011

Condition:   Human Papillomavirus Infection
Intervention:  
Sponsors:   Sanford Health;   Sanford Health
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Drug: Prohibitin-TP01
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Sunitinib;   Drug: Dasatinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Ortho Biotech, Inc.;   Pfizer
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: telephone-based intervention;   Other: counseling intervention;   Other: educational intervention;   Procedure: therapeutic dietary intervention
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Adenocarcinoma of the Prostate;   Castrate Resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions:   Drug: docetaxel;   Procedure: prostate biopsy;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Drug: phenelzine sulfate
Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Castrate-Resistant Prostate Cancer
Interventions:   Drug: ISIS EIF4E Rx;   Drug: ISIS EIF4E Rx;   Drug: ISIS EIF4E Rx;   Drug: Prednisone;   Drug: Docetaxel
Sponsors:   Isis Pharmaceuticals;   Isis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: tasquinimod
Sponsors:   Active Biotech AB;   Active Biotech AB
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: 18F-DCFBC
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2011

Condition:   Prostate Cancer
Interventions:   Radiation: Proton Radiation;   Radiation: Proton Radiation
Sponsors:   Proton Collaborative Group;   Proton Collaborative Group
Recruiting - verified April 2012

Conditions:   Prostate Cancer Treated by Radiosurgery Early Risk;   Prostate Cancer Treated by Radiosurgery Intermediate Risk
Intervention:  
Sponsors:   Florida Robotic Radiosurgery Association;   Florida Robotic Radiosurgery Association
Recruiting - verified April 2012

Condition:   Prostate Neoplasms
Intervention:   Drug: ASG-5ME
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Seattle Genetics, Inc.
Recruiting - verified March 2012

Condition:   NY-ESO-1 Positive Solid Tumors or Melanoma
Intervention:   Biological: IMF-001
Sponsors:   ImmunoFrontier, Inc.;   ImmunoFrontier, Inc.
Recruiting - verified January 2012

Conditions:   Clinical Stage T2b or Less of Prostate Cancer;   Prostate Brachytherapy;   Transrectal Prostate Ultrasound Treatment Planning
Interventions:   Other: An ultrasound-based technique to identify prostate cancer;   Other: pre-implant transrectal ultrasound images and planning;   Other: ultrasound-based cancer-specific images
Sponsors:   Beth Israel Medical Center;   Beth Israel Medical Center;   Riverside Research Instutute,New York, NY
Recruiting - verified January 2012

Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention:   Drug: Abiraterone Acetate
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: MDV3100;   Drug: Placebo
Sponsors:   Medivation, Inc.;   Medivation, Inc.;   Astellas Pharma Inc
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:   Drug: zoledronate therapy
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   Department of Defense
Recruiting - verified November 2011

Condition:   Hormone Refractory Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: TroVax + Docetaxel
Sponsors:   Oxford BioMedica;   Oxford BioMedica;   MedSource
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: Orteronel + prednisone;   Drug: Placebo + prednisone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Conditions:   Non-Small Cell Lung Neoplasms;   Prostate Neoplasms;   Bladder Neoplasms;   Ovarian Neoplasms;   Breast Neoplasms
Intervention:   Drug: MGAH22
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Custirsen Sodium, Docetaxel, Prednisone;   Drug: Docetaxel, Prednisone
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries;   OncoGenex Technologies
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Leuprolide Acetate;   Drug: Ipilimumab;   Procedure: Radical Prostatectomy
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Recruiting - verified May 2012

Conditions:   Cancer;   Lymphoma;   Prostate;   Melanoma
Intervention:   Drug: PNT2258
Sponsors:   Pronai Therapeutics, Inc;   Pronai Therapeutics, Inc
Recruiting - verified June 2011

Condition:   Advanced Cancers
Interventions:   Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Lenalidomide;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: ARN-509
Sponsors:   Aragon Pharmaceuticals, Inc.;   Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Drug: GE-148 (18F)
Sponsors:   GE Healthcare;   GE Healthcare;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Biological: Cancer Macrobead placement in abdominal cavity
Sponsors:   The Rogosin Institute;   The Rogosin Institute
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Dietary Supplement: finasteride and Isoflavones
Sponsors:   University of Kansas;   University of Kansas
Recruiting - verified October 2011

Conditions:   Prostate Cancer;   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: vorinostat;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography/computed tomography
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Drug: Digoxin
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
Recruiting - verified January 2012

Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Tadalafil;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Drug: doxorubicin-GnRH agonist conjugate AEZS-108
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   AEterna Zentaris
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Biological: fowlpox-PSA-TRICOM vaccine;   Biological: vaccinia-PSA-TRICOM vaccine;   Drug: docetaxel;   Drug: prednisone
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Other: MRI examination
Sponsors:   Radboud University;   Radboud University;   Siemens AG;   Mount Vernon Hospital;   Multi-Imagem and CDPI, Rio de Janeiro, Brasil;   Norwegian University of Science and Technology;   University of California, Los Angeles;   University Hospital, Ghent;   Johns Hopkins University;   German Cancer Research Center;   Medical University of Vienna;   University Health Network, Toronto;   University of Heidelberg
Recruiting - verified July 2011

Condition:   Prostate Cancer
Interventions:   Biological: engineered autologous T cells;   Drug: cyclophosphamide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Department of Defense
Recruiting - verified March 2012

Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer
Interventions:   Dietary Supplement: genistein;   Other: placebo;   Procedure: therapeutic conventional surgery
Sponsors:   Northwestern University;   Northwestern University;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Biological: cixutumumab;   Drug: bicalutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Castration Resistant Prostate Cancer
Interventions:   Drug: OGX-427 and Prednisone;   Drug: Prednisone
Sponsors:   British Columbia Cancer Agency;   British Columbia Cancer Agency;   OncoGenex Technologies, Inc.
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Drug: ZD4054
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   AstraZeneca
Recruiting - verified November 2011

Conditions:   Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Intervention:   Radiation: intensity modulated external beam radiation therapy
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University
Recruiting - verified January 2012

Conditions:   Bone Metastases;   Castration-Resistant Prostate Cancer
Interventions:   Drug: Alpharadin® (Radium-223 chloride) + docetaxel;   Drug: Docetaxel
Sponsors:   Algeta ASA;   Algeta ASA;   Bayer
Recruiting - verified October 2011

Condition:   Prostate Cancer
Interventions:   Other: Placebo;   Drug: SM;   Drug: Third Group;   Drug: Fourth Group
Sponsors:   Penn State University;   Penn State University
Recruiting - verified July 2011

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified February 2012

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions:   Drug: lenalidomide;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   Interstitial Cystitis;   Chronic Prostatitis
Intervention:  
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Colorado, Denver
Recruiting - verified December 2011

Conditions:   Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention:   Drug: TRC105
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Advanced Solid Tumors;   Adenocarcinoma of the Prostate
Intervention:   Drug: MLN8237 plus docetaxel
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: LHRHa
Sponsors:   Cougar Biotechnology, Inc.;   Cougar Biotechnology, Inc.
Recruiting - verified December 2010

Condition:   Prostate Cancer
Interventions:   Drug: Testosterone;   Drug: Etoposide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   University of Florida;   University of Florida
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Radiation: Hypo-fractionated radiotherapy
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles
Recruiting - verified February 2012

Conditions:   Ovarian Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Colorectal Cancer;   Gastric Cancer;   Esophageal Cancer;   Cancer of Head and Neck
Interventions:   Drug: LY2523355;   Drug: pegfilgrastim
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer
Interventions:   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Drug: cinacalcet hydrochloride
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Advanced Cancer
Interventions:   Drug: Docetaxel (Taxotere);   Drug: Sirolimus (Rapamycin);   Drug: Prednisone
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: raloxifene;   Procedure: quality-of-life assessment
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified January 2012

Condition:   Locally Advanced Prostate Cancer
Intervention:   Biological: TNFerade™ Biologic
Sponsors:   GenVec;   GenVec;   National Institutes of Health (NIH)
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Radiation: CyberKnife Radiosurgery;   Radiation: CyberKnife Radiosurgery
Sponsors:   CyberKnife Centers of San Diego;   CyberKnife Centers of San Diego
Recruiting - verified September 2011

Condition:   Prostate Cancer
Interventions:   Procedure: Proton Beam Radiation Therapy;   Other: Quality-of-Life assessment;   Other: Questionnaire Administration
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Radiation: Proton Therapy , proton boost and docetaxel followed by androgen deprivation;   Radiation: Conformal X-ray , proton boost and docetaxel followed by androgen deprivation
Sponsors:   University of Florida;   University of Florida
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Drug: Purified isoflavones;   Drug: Methyl cellulose blend
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Center on Minority Health and Health Disparities (NCMHD)
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ketoconazole, hydrocortisone;   Drug: Ketoconazole, dexamethasone
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified March 2012

Conditions:   Adenocarcinoma of the Prostate;   Stage II Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Drug: abiraterone acetate;   Drug: prednisone;   Drug: leuprolide acetate;   Other: mass spectrometry;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Radiation: external beam radiation therapy;   Drug: goserelin acetate
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Hereditary Prostate Cancer;   Prostate Cancer
Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: study of high risk factors
Sponsors:   Portland VA Medical Center;   Portland VA Medical Center
Recruiting - verified November 2009

Condition:   Prostate Cancer
Intervention:   Procedure: Prostatectomy
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified January 2012

Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
Intervention:   Drug: MCS-2
Sponsors:   Health Ever Bio-Tech Co., Ltd.;   Health Ever Bio-Tech Co., Ltd.
Recruiting - verified June 2011

Conditions:   Lower Urinary Tract Symptoms;   Benign Prostatic Hyperplasia
Interventions:   Drug: MCS-2 15 mg/day;   Drug: MCS-2 30 mg/day;   Drug: Placebo
Sponsors:   Health Ever Bio-Tech Co., Ltd.;   Health Ever Bio-Tech Co., Ltd.
Recruiting - verified November 2011

Condition:   Stage III Prostate Cancer
Interventions:   Dietary Supplement: omega-3 fatty acid;   Other: bone scan;   Other: dual x-ray absorptometry;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Metastatic Prostate Cancer
Intervention:  
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Prostate Cancer;   Lung Cancer;   Lymphoma Cancer;   Gynecological Cancers
Interventions:   Behavioral: group intervention and questionnaires;   Behavioral: individual phone intervention and questionnaires
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011

Condition:   Bone Metastases
Intervention:   Device: ExAblate 2100
Sponsors:   InSightec;   InSightec
Recruiting - verified October 2011

Condition:   Prostate Cancer
Intervention:   Radiation: Stereotactic Body Radiation Therapy
Sponsors:   University of Pittsburgh;   University of Pittsburgh
Recruiting - verified July 2011

Condition:   Prostate Cancer
Interventions:   Genetic: DNA analysis;   Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Radiation: Stereotactic Radiosurgery using the Novalis Tx
Sponsors:   San Diego Radiosurgery;   San Diego Radiosurgery
Recruiting - verified August 2011

Condition:   Prostate Cancer
Interventions:   Radiation: Proton Therapy;   Radiation: Photon, Proton and Hormonal Therapy;   Radiation: Proton Therapy;   Radiation: Photon, Proton and Hormonal Therapy
Sponsors:   University of Florida;   University of Florida
Recruiting - verified March 2012

Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: S-equol;   Drug: Placebo
Sponsors:   Ausio Pharmaceuticals, LLC;   Ausio Pharmaceuticals, LLC
Recruiting - verified September 2011

Condition:   Prostate Cancer
Interventions:   Drug: vitamin D3;   Drug: Placebo daily for one year
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified March 2012

Conditions:   Peripheral Nerve Injury;   Prostate Cancer;   Radical Prostatectomy;   Nerve Reconstruction;   Cavernous Nerve Injury
Intervention:   Other: Processed Human Nerve Tissue Scaffold
Sponsors:   AxoGen, Inc;   AxoGen, Inc
Recruiting - verified February 2012

Condition:   Benign Prostatic Hyperplasia (BPH)
Interventions:   Drug: NX-1207;   Drug: Placebo
Sponsors:   Nymox Corporation;   Nymox Corporation
Recruiting - verified March 2012

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Metastatic Prostate Cancer
Interventions:   Drug: Bevacizumab;   Drug: Lenalidomide;   Drug: Docetaxel;   Drug: Prednisone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:   Radiation: SBRT Prostate
Sponsors:   Duke University;   Duke University
Recruiting - verified September 2011

Conditions:   Urinary Incontinence;   Prostate Cancer
Intervention:   Device: Surgisis Male Sling
Sponsors:   Cook;   Cook
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine;   Johns Hopkins University;   National Cancer Institute (NCI);   Wake Forest University
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: leuprolide acetate;   Drug: goserelin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Cancer;   Cataract;   Low Bone Mineral Density;   Osteopenia;   Osteoporosis;   Prostate Cancer
Interventions:   Biological: Denosumab;   Biological: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified March 2012

Condition:   Hormone Refractory Prostate Cancer
Intervention:   Drug: IV administration of fluorine-18 labeled methylcholine followed by PET/CT
Sponsors:   Queen's Medical Centre;   Queen's Medical Centre;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Drug: IV administration of fluorine-18 methylcholine followed by PET/CT imaging
Sponsors:   Queen's Medical Centre;   Queen's Medical Centre;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: NX-1207;   Drug: Placebo
Sponsors:   Nymox Corporation;   Nymox Corporation
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Healthy Volunteer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Prostate Cancer
Intervention:   Drug: torisel
Sponsors:   Oncology Specialists, S.C.;   Oncology Specialists, S.C.;   Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified August 2010

Conditions:   Cervical Cancer;   Endometrial Cancer;   Esophageal Cancer;   Prostate Cancer;   Biliary Cancer
Intervention:   Procedure: Brachytherapy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Adenocarcinoma
Intervention:   Radiation: Hypofractionated, image-guided, intensity-modulated external beam radiation
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Montefiore Medical Center
Recruiting - verified March 2012

Condition:   Cancer
Interventions:   Procedure: ultrasound hyperthermia treatment;   Radiation: brachytherapy
Sponsors:   National Cancer Institute (NCI);   University of California, San Francisco;   National Cancer Institute (NCI)
Recruiting - verified May 2009

Conditions:   Impotence;   Prostatic Neoplasms
Interventions:   Drug: Sildenafil therapy plus post-NSRRP HBO2T;   Drug: Sildenafil therapy plus sham post-NSRRP HBO2T
Sponsors:   Hartford Hospital;   Hartford Hospital
Recruiting - verified April 2011

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: vitamin E;   Procedure: sham intervention
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Drug: Ketoconazole
Sponsors:   University of California, Davis;   University of California, Davis
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: oral microencapsulated diindolylmethane;   Other: high performance liquid chromatography;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage II Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions:   Dietary Supplement: cholecalciferol;   Drug: Placebo Administration
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified January 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasms
Interventions:   Drug: Panobinostat (Phase II doses);   Drug: Panobinostat
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Novartis
Recruiting - verified March 2012

Condition:   Bone Metastases
Intervention:   Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors:   American College of Radiology - Image Metrix;   American College of Radiology - Image Metrix;   Academy of Molecular Imaging
Recruiting - verified June 2011

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Procedure: Cryoablation
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Endocare, Inc.;   Gen-Probe, Incorporated;   FirmaMed;   Envisioneering Medical Technologies
Recruiting - verified April 2012

Conditions:   Cancer Survivor;   Depression;   Gastrointestinal Complications;   Male Erectile Disorder;   Prostate Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Urinary Complications
Interventions:   Behavioral: telephone-based intervention;   Other: educational intervention;   Other: partner-assisted coping skills training;   Other: questionnaire administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   East Carolina University;   East Carolina University;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Lahey Clinic;   Lahey Clinic
Recruiting - verified June 2011

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Recurrent Prostate Cancer
Intervention:   Radiation: CyberKnife Radiosurgery
Sponsors:   CyberKnife Centers of San Diego;   CyberKnife Centers of San Diego
Recruiting - verified September 2011

Condition:   Prostate
Intervention:   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified November 2011

Conditions:   Cancer;   Fatigue
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Nursing Research (NINR)
Recruiting - verified October 2011

Condition:   Prostate Cancer
Interventions:   Biological: pTVG-HP with rhGM-CSF;   Biological: pTVG-HP with rhGM-CSF
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Low Testosterone Levels;   Erectile Dysfunction
Interventions:   Drug: Testim® + Viagra®;   Drug: Placebo Testim® + Viagra®
Sponsors:   Baylor College of Medicine;   Mohit Khera
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Radiation: Proton Radiation;   Radiation: Proton
Sponsors:   Loma Linda University;   Loma Linda University
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: TK1258
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Other: Information Gathering;   Other: Decision Aid
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Prostate Cancer Related Fatigue
Intervention:   Behavioral: Exercise
Sponsors:   University of Rochester;   University of Rochester;   Department of Defense
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Radiation: hypofractionation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012

Condition:   Cancer
Interventions:   Drug: hydroxychloroquine;   Drug: sunitinib malate
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Prostate Cancer
Interventions:   Behavioral: Group Meetings;   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Biological: Ad5-CMV-NIS;   Drug: liothyronine sodium;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Radiation: iodine I 131
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Androgen Deprivation Therapy;   Drug: bicalutamide;   Drug: bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Genentech;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Cancer Institute of New Jersey
Recruiting - verified February 2012

Condition:   Recurrent Prostate Cancer
Intervention:   Device: High Intensity Focused Ultrasound
Sponsors:   USHIFU, LLC;   USHIFU, LLC
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Elevated Prostate Specific Antigen (PSA)
Intervention:   Other: serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   National Institutes of Health (NIH);   New York Presbyterian Hospital;   Weill Medical College of Cornell University;   State University of New York - Downstate Medical Center;   New York University School of Medicine;   Kings County Hospital
Recruiting - verified January 2012

Condition:   Prostatic Neoplasms
Intervention:  
Sponsors:   University of Washington;   University of Washington;   Canary Foundation;   Early Detection Research Network
Recruiting - verified June 2011

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: selenomethionine;   Drug: finasteride;   Other: placebo
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: hydroxychloroquine
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Biological: peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant)
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Institutes of Health (NIH)
Recruiting - verified January 2012

Conditions:   Cancer;   Solid Tumor
Intervention:   Drug: CALAA-01
Sponsors:   Calando Pharmaceuticals;   Calando Pharmaceuticals
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: green tea;   Dietary Supplement: placebo
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: Dutasteride;   Drug: Placebo
Sponsors:   NorthShore University HealthSystem Research Institute;   NorthShore University HealthSystem Research Institute;   University of Chicago;   Northwestern University
Recruiting - verified April 2008

Conditions:   Aging;   Insulin Resistance
Interventions:   Drug: Testosterone;   Drug: Estrogen
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified January 2012

Condition:   Prostate Cancer
Intervention:   Dietary Supplement: Prostate Health Cocktail
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
Recruiting - verified November 2011

Conditions:   Prostatitis;   Cystitis, Interstitial;   Urinary Bladder, Overactive;   Chronic Pelvic Pain Syndrome;   Painful Bladder Syndrome
Intervention:  
Sponsors:   Beth Israel Deaconess Medical Center;   Beth Israel Deaconess Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011

Condition:   Prostate Cancer
Intervention:   Biological: Gene Modified T Cells
Sponsors:   Roger Williams Medical Center;   Roger Williams Medical Center
Recruiting - verified January 2012

Conditions:   Chronic Prostatitis With Chronic Pelvic Pain Syndrome;   Chronic Bacterial Prostatitis;   Asymptomatic Inflammatory Prostatitis;   Painful Bladder Syndrome;   Cystitis, Interstitial
Intervention:   Genetic: Genomic and proteomic biomarker discovery
Sponsors:   Beth Israel Deaconess Medical Center;   Beth Israel Deaconess Medical Center
Recruiting - verified June 2011

Condition:   Prostate Cancer
Intervention:   Drug: Revlimid
Sponsors:   Oncology Specialists, S.C.;   Oncology Specialists, S.C.;   Celgene Corporation
Recruiting - verified August 2010

Conditions:   Bone Metastases;   Multiple Myeloma
Interventions:   Device: ExAblate 2000;   Device: Sham
Sponsors:   InSightec;   InSightec
Recruiting - verified October 2011

Conditions:   Localized Breast Cancer;   Localized Prostate Cancer;   Patients Receiving External Beam Radiotherapy
Interventions:   Dietary Supplement: Organic Germanium;   Dietary Supplement: Placebo
Sponsors:   Arizona Oncology Services;   Arizona Oncology Services
Recruiting - verified June 2011

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: paricalcitol;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Procedure: dual x-ray absorptometry;   Procedure: quality-of-life assessment
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified October 2010

Condition:   Prostatic Hyperplasia
Interventions:   Drug: Polyphenon E;   Drug: placebo
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: Interview;   Behavioral: survey instruments using Web-Based Data Collection System (WBDC) survey content
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Behavioral: questionnaires of quality of life
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University School of Medicine(VA-NYU);   State University of New York - Downstate Medical Center;   Kings County Hospital Center
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Drug: lovastatin
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   Hunter Holmes Mcguire Veteran Affairs Medical Center
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   MRI
Intervention:   Other: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Behavioral: Questionaires;   Behavioral: Questionaires
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI);   City of Hope National Medical Center;   Fordham University;   Columbia University;   New York University Medical Center
Recruiting - verified March 2012

Condition:   Prostate Cancer
Intervention:   Other: Whole Blood Draw
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012

Condition:   Hormone Refractory Prostate Cancer
Intervention:   Biological: ADENOVIRUS/PSA VACCINE
Sponsors:   University of Iowa;   University of Iowa;   Department of Defense
Recruiting - verified March 2012

Condition:   Recurrent Prostate Cancer
Intervention:   Biological: Adenovirus/PSA Vaccine
Sponsors:   University of Iowa;   University of Iowa;   Department of Defense
Recruiting - verified March 2012

Conditions:   Breast Cancer;   Colon Cancer;   Prostate Cancer
Intervention:   Genetic: PCR/PCR/LDR Strategy
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Columbia University;   Weill Medical College of Cornell University
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Drug: RAD001, Docetaxel, Bevacizumab
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   Novartis;   Genentech;   University of Southern California
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Rockefeller University;   Flinders Medical Centre;   Aureon Biosciences, Inc.;   University of Southern California;   Gen-Probe, Incorporated;   Genentech;   General Electric;   Purdue University;   Biocept, Inc.;   Duke University;   Ikonysis, New Haven, CT;   Array Genomics;   Cold Spring Harbor Laboratory
Recruiting - verified December 2011

Conditions:   Prostate Cancer;   Quality of Life
Intervention:   Behavioral: Quality of Life Questionnaires
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   The Cleveland Clinic
Recruiting - verified December 2011

Conditions:   Adrenal Cortical Cancer;   Brain Cancer;   Breast Cancer;   CNS Cancer;   Colon Cancer;   HEENT Cancer;   Hodgkin's Disease;   Kaposi's Sarcoma;   Liver Cancer;   Lung Cancer;   Non-Hodgkin's Lymphoma;   Ovarian Cancer;   Pancreatic Cancer;   Prostate Cancer;   Rectal Cancer;   Renal Cancer;   Sarcoma;   Squamous Cell Carcinoma;   Thyroid Cancer
Interventions:   Device: Proton-decoupled 31P MRS at 1.5T;   Device: 1H Spectroscopy at 1.5T and 3T
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Columbia University;   University of Pennsylvania;   St.George's Hospital (England);   Royal Marsden NHS Foundation Trust;   University Medical Center Nijmegen;   Weill Medical College of Cornell University
Recruiting - verified February 2012

Conditions:   Cancer;   Prostate
Interventions:   Drug: Simvastatin;   Other: Placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   Oregon Health and Science University
Recruiting - verified May 2012

Conditions:   Breast Neoplasms;   Ovarian Neoplasms;   Colonic Neoplasms;   Prostatic Neoplasms;   Uterine Cervical Neoplasms;   Leukemia;   Lymphoma, Non-Hodgkin
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:   Drug: [18F]FACBC
Sponsors:   Emory University;   David M. Schuster, MD
Recruiting - verified December 2011

Condition:   Prostate Cancer
Intervention:   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: calcitriol;   Drug: ketoconazole;   Drug: therapeutic hydrocortisone
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Department of Defense
Recruiting - verified January 2012

Condition:   Prostate Cancer
Interventions:   Procedure: Brachytherapy;   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: cholecalciferol;   Dietary Supplement: genistein;   Dietary Supplement: soy isoflavones;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Prostate Cancer;   Pain
Interventions:   Drug: Azacitidine;   Drug: Docetaxel;   Drug: Prednisone;   Genetic: Azacitidine induced demethylation of repetitive elements.;   Genetic: GADD45α methylation and expression in prostate cancer tissue;   Genetic: GADD45α methylation in serum DNA
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012

Conditions:   Chronic Prostatitis (CP);   Chronic Pelvic Pain Syndrome (CPPS);   Painful Bladder Syndrome (PBS);   Benign Frequency Syndrome (BFS);   Benign Daytime Frequency Syndrome (BDFS)
Intervention:  
Sponsors:   Children's Hospital Boston;   Children's Hospital Boston;   National Institutes of Health (NIH)
Recruiting - verified July 2011

Condition:   Prostate Cancer
Intervention:   Behavioral: Survey
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified December 2011

Conditions:   Obesity;   Prostate Cancer
Interventions:   Behavioral: Weight Loss;   Other: No Weight Loss Group
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Procedure: 3T Magnetic Resonance Spectroscopic Imaging
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Department of Defense
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Radiation: Samarium Sm 153 lexidronam pentasodium;   Biological: Sargramostim;   Biological: Recombinant vaccinia-TRICOM vaccine;   Biological: Recombinant fowlpox-TRICOM vaccine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Flutamide;   Biological: Sargramostim;   Biological: recombinant fowlpox-prostate apecific antigen vaccine;   Biological: recombinant vaccinia prostate specific antigen vaccine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Prostate Cancer
Intervention:   Behavioral: type of decision aid
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: docetaxel;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Procedure: conventional surgery
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified September 2011

Condition:   Prostate Cancer
Interventions:   Procedure: AIR-MRSI;   Procedure: PFC-MRSI
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:   Drug: Gleevec + Sorafenib
Sponsors:   Oncology Specialists, S.C.;   Oncology Specialists, S.C.
Recruiting - verified August 2010

Condition:   Prostate Cancer
Intervention:   Drug: Sorafenib
Sponsors:   Oncology Specialists, S.C.;   Oncology Specialists, S.C.
Recruiting - verified August 2010

Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prolieve® Thermodilatation System
Sponsors:   Boston Scientific Corporation;   Boston Scientific Corporation
Recruiting - verified June 2011

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Lung Cancer;   Metastatic Cancer;   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   American College of Surgeons;   Eastern Cooperative Oncology Group;   Radiation Therapy Oncology Group
Recruiting - verified July 2011

Condition:   Prostate Cancer
Interventions:   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: physiologic testing;   Procedure: computed tomography
Sponsors:   National Cancer Institute (NCI);   University of California, San Francisco;   National Cancer Institute (NCI)
Recruiting - verified October 2006

Conditions:   Prostatic Neoplasms;   Prostate Cancer
Intervention:  
Sponsors:   Stanford University;   Stanford University
Recruiting - verified May 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Device: hybrid PET-CT imaging system
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Intraabdominal Cancers (Various Types)
Intervention:   Biological: Implantation of cancer macrobeads in the abdominal cavity by laparoscopy
Sponsors:   The Rogosin Institute;   The Rogosin Institute
Recruiting - verified April 2012

Condition:   Prostate Cancer
Intervention:  
Sponsors:   Stanford University;   Stanford University
Recruiting - verified June 2011

Conditions:   Benign Prostatic Hyperplasia;   Enlarged Prostate
Intervention:   Other: Registry and Database
Sponsors:   Indiana Kidney Stone Institute;   Indiana Kidney Stone Institute
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: Prednisone
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   Sanofi-Aventis
Recruiting - verified September 2011

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: Androgen Hormonal Suppression and Radiation;   Drug: Androgen Suppression Therapy and Radiation Therapy
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Sanofi-Aventis
Recruiting - verified June 2011

Conditions:   Premenstrual Syndrome;   PMS;   Healthy;   Depression
Interventions:   Drug: Dutasteride;   Drug: Placebo oral capsule
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified April 2012

Conditions:   Leiomyomatosis;   Kidney Neoplasms
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012